Brenda Maloney Shafer, Richie Davis and Michael French Quoted in Bloomberg Law Article About Discussion Around Changes to 340B Drug Discount Program
Quarles & Brady Health & Life Sciences attorneys Brenda Maloney Shafer, Richie Davis and Michael French provided perspective for a Bloomberg Law article about a push by stakeholders for Congress to make some revisions to the 340B drug discount program.
A bipartisan group of senators recently solicited feedback on ways to improve the program, and a variety of stakeholders made suggestions regarding the guidelines on who can participate and policies to ensure greater transparency and oversight of the 340B program. Shafer (national vice chair of the Health & Life Sciences Practice Group), Davis and French (both associates in the group) said legislative action is needed to strengthen the program.
Senators asking for information also “signaled a desire to find some type of compromise to put the program on surer footing moving forward,” said Brenda Shafer, Richard Davis, and Michael French of Quarles & Brady LLP.
“This much uncertainty is ultimately unsustainable—some type of legislative fix is likely needed to ensure that all stakeholders know and play by the same clear rules, and can stop operating in such a gray space without clear guidelines,” the Quarles & Brady LLP attorneys said.